SARMS | PEPTIDES
Highest Quality & Efficiency

Popular Sarms and Peptides

Ostarine MK-2866
57.00 
Andarine S4
55.00 
GW-1516 Endurobol
55.00 
RAD140 Testolone
145.00 
Ibutamoren MK-677
167.00 
SR9009 Stenabolic
143.00 
Melanotan 2
25.00 
Follistatin-344
87.00 
IGF-1 LR3
64.00 
CJC-1295
45.00 
TB-500
31.00 
GHRP-6
15.00 
Only Finest Quality

SARMs & Peptides

With Highest Efficiency
Only Finest Quality
Wide Offer

Best Possible Prices

Excellent Services
Wide Offer
Serious Approach

Fastest Possible Delivery

We Care About All
Serious Approach

SARMS SALE INTRODUCTION

Welcome to the sarms sale e-shop website. If you are looking for and want to buy sarms and peptides in the best possible quality, and at affordable prices, you are definitely right here. 

All sarms and peptides are regularly and strictly tested for best quality, and meet the highest requirements and demands required by professional and top research. In their production, great emphasis is placed on achieving maximum pharmaceutical grade purity and the highest possible efficiency. We are proud to be able to offer you the highest quality and most effective sarms and peptides you can ever buy. And always the perfect ratio of quality and prices. 

However, by providing first-class and highest quality sarms and peptide products for sale for you, our services and the pursuit of perfection certainly do not end. For your satisfaction, we make the maximum of our efforts and we always do our best in every aspect, we care about every detail, we simply make sure that you get the maximum possible for us with your money and complete perfect services to your perfect satisfaction. 

Friendly communication and friendly approach to customers, seriousness and always decent and fair dealing, fast processing of your orders, the fastest possible delivery to you, and striving to meet your requirements, needs and demands as much as possible they are a matter of course for us. Every single customer and his satisfaction are important to us. 

The widest range of sarms and peptides on the market, the highest possible quality at great prices and excellent complete customer service, is what characterizes our efforts and goals in one sentence. We look forward to working with you and we really appreciate your trust, it is our commitment to do things as best we can. Thank you! Sincerely, your sarms sale team.

SARMs – Selective Androgen Receptor Modulators

What are SARMs? Selective androgen receptor modulators – SARMs are synthetic compounds which belong to the class of androgen receptor ligands and bind with high affinity to androgen receptors (AR). The main goal and positive effects of SARMs are mainly their strong anabolic properties and ability to induce a rapid increase in protein synthesis and hypertrophy in muscle tissues (hypertrophy is an increase in the volume of skeletal muscle cells), and have a positive effect on increasing bone density and their mineralization. 

Thanks to these properties, the effectiveness of SARMs to support the growth, development and maintenance of muscle mass and bone density in this regard is comparable to the effectiveness of AAS (anabolic-androgenic steroids),  which are generally considered to be one of the most effective for this purpose. 

However, an enormous advantage of SARMs over anabolic steroids , testosterone and its derivatives is the fact that SARMs present significantly fewer possible and significantly less serious side effects and health problems or risks, that the use of anabolic-androgenic steroids can and often does cause. These advantages of SARMs are ensured by their high selectivity – their properties and ability to bind preferentially to androgen receptors where desired – in muscles and bones, and at the same time act as little as possible on tissues and organs where it is undesirable and harmful (prostate, liver, kidneys, skin, etc.) 

Thus, SARMs have a many times higher ratio of desired – anabolic effects compared to adverse – androgenic effects. All of these listed positive features and benefits of SARMs make them hot candidates for research around the world, and very promising substances for use in the future to treat diseases related to muscle loss or thinning bone density. Due to their excellent ability to support the growth of muscle mass and a much better safety profile compared to anabolic steroids, SARMs are also often sought after and experimentally used by bodybuilders to build muscle mass.

History of SARMs

Efforts to create new contraceptives have led scientists to discover and develop SERMs – selective modulators of estrogen receptors (ER), synthetic compounds that act on estrogen receptors (unlike SARMs, which act on a completely different receptor – the androgen receptor). The discovery of SERMs for many years preceded the discovery and development of the first SARMs. The first SERM Clomifene was developed by chemist Frank Palopoli and his scientific team in the late 1950s, who subsequently published the results of his first clinical studies. Mr Palopoli has also carried out successful research into the use of another SERM tamoxifen in the treatment of breast cancer and other tumors. 

The discovery in 1987 showed that the SERMs tamoxifen and raloxifene, which were considered antiestrogens due to potent antagonistic effects in breast tissue, may be useful in preventing bone loss due to their estrogenic effects, and had a major impact on understanding estrogen receptor and nuclear receptor function. The term SERM was introduced to refer to these compounds that have a combination of estrogen agonist, partial agonist or antagonist activities depending on the tissue. The successes achieved in the development of SERMs, the knowledge gained and a better understanding of the mechanisms of their action, as well as the growing use of tamoxifen in the treatment of breast cancer, have led other scientists to the idea and effort to develop also their androgen receptor modulating analogues – selective andorogenic receptor modulators (SARMs), and the subsequent development of SARMs began in the 1990s

The modern era of nonsteroidal SARMs began independently at Ligand Pharmaceuticals, and the scientific work of Duane D. Miller and Jim Dalton, who were colleagues at the University of Tennessee Health Science Center.  Researchers at Ligand Pharmaceuticals were the first to develop a series of cyclic quinolinones that had anabolic activity and some degree of tissue selectivity for skeletal muscle, and became the basis for their SARM LG121071  (LGD-121071). The discovery of Dalton and Miller that aryl propionamides with structural similarity to bicalutamide and hydroxyflutamide can activate AR-dependent transcriptional activity provided the basis for the development of the diaryl propionamide class SARM (Ostarine, Andarine etc.). Over the last 20 years, the number of bioactive SARMs studied has grown steadily, as has scientists’ knowledge of the mechanisms of action of SARMs.

The androgen receptor (AR)

The androgen receptor (AR, or also known as NR3C4 (nuclear receptor subfamily 3, group C, gene 4)) belongs to the superfamily of nuclear steroid hormone receptors and the binding of Testosterone and dihydroxytestosterone, which are its natural endogenous ligands, modulates its function as a transcription factor. In human beings, the androgen receptor (MW 110 kDa; 919-920 amino acids) is encoded by the AR gene located on the long arm chromosome X at the locus Xq11- Xq12, and is expressed in various tissues such as skeletal muscle, testes, prostate, breast, uterus and others.  The effects of the interaction between AR and androgens are complex and vary depending on gender, age, tissue type and hormonal status.  Androgen receptor also has many other important effects, such as effects on bone density, strength, muscle mass, hematopoiesis, clotting or metabolism. 

Function of the androgen receptor, androgen receptor binding
Function of the androgen receptor: Testosterone enters the cell and, if 5-alpha-reductase is present, is converted into dihydrotestosterone (DHT). Upon steroid binding, the androgen receptor (AR) undergoes a conformational change and releases heat-shock proteins (hsps). Phosphorylation (P) occurs before or after steroid binding. The androgen receptor translocates to the cell nucleus where dimerization, DNA binding, and the recruitment of coactivators occur. Target genes are transcribed (mRNA) and translated into proteins.

How do SARMS work?

Mechanisms of action of SARMs: Androgen receptor functions as a cell nuclear receptor. SARM, which is its synthetic ligand, enters the cell, usually by diffusion, and encounters unoccupied AR in the cytoplasm. After binding, AR dissociates from cytosolic heat shock proteins and migrates to the nucleus, where it associates with various co-regulatory proteins. The complex then interacts with specific DNA sequences and acts as a regulator of transcription of androgen-responsive genes. A complex and tissue-specific process determines the transcriptional and thus the cellular response.  Although much scientific work has been done to determine how different SARMs achieve tissue specificity and partial agonism, the exact mechanisms remain unclear to this day. 

Thus, the ability of SARMs to signal through AR appears to depend on how their unique conformations interact with functional AR domains, and on how these domains interact with the cellular regulatory environment to target DNA expression. Whereas each SARM-AR complex has a different conformation and that the tissues have unique AR expression patterns, levels of co-regulatory proteins and transcriptional regulation, we can imagine the great diversity and potential for tissue-specific and/or action-specific SARMs.

How do SARMS work? Mechanisms of action of SARMs
SARMs enter the cytoplasm, where they displace the androgen receptor from heat shock proteins. Once bound, they translocate to the cell nucleus and act as transcription factors by binding androgen response elements (AREs). Depending on the tissue type and regulatory environment of the cell, different co-regulatory proteins help determine and modulate the transcriptional response. Legend: HSP = Heat shock protein, AR = Androgen Receptor, ARE = Androgen Response Elements.

SARMs and muscle growth

The most valuable positive effect of SARMs include their strong anabolic properties and action on skeletal muscle in combination with the fact that their anabolic and androgenic effects can be preferentially and highly selectively targeted to these muscle tissues. By acting on and binding to the androgen receptors of muscle cells, SARMs highly effectively stimulate increased protein synthesis and hypertrophy in skeletal muscle tissues (i.e., they stimulate the growth and increase in the volume of their muscle cells).

SARMs are able to significantly support the growth and maintenance of lean muscle mass, similar to the endogenous ligands AR – the steroid hormones testosterone and DHT (dihydroxytestosterone) or their synthetic derivatives – anabolic androgenic steroids (AAS), however, they represent the minimum possible side effects, health problems and risks that the use of testosterone or anabolic-androgenic steroids brings.

The most promising potential applications of Selective androgen receptor modulators include conditions associated with muscle loss (cachexia, muscular dystrophies).  In healthy normal individuals, there is an equilibrium muscle between breakdown and synthesis, and any change in the rate of degradation or protein synthesis may favor atrophy (loss of muscle mass) or hypertrophy (muscle cell growth). Many scientific and clinical studies have been performed to demonstrate the strong ability of SARMs to induce muscle hypertrophy – muscle cell growth in skeletal muscle tissue, prevent muscle arthrophy (loss of muscle mass) and reverse iatrogenic and disease-induced catabolism, with minimal or beneficial antagonist activity on androgenic tissues.

Since SARMs have excellent ability to effectively support muscle growth and at the same time a many times better safety profile than testosterone and anabolic steroids, it is logical that they have also come to the attention of bodybuilders and strength athletes who experiment with using them for more massive muscle and strength growth, and increase performance. In 2008, the World Anti-Doping Agency (WADA) banned SARMs in sport due to their potential for abuse to gain unfair advantage in physical competitions. The use of SARMs in athletes has since been considered doping and is banned by most sports entities.

Undesirable and harmful effects of anabolic steroids

It is generally well known that anabolic-androgenic steroids (AAS) are very effective in stimulating muscle growth (as well as strength and performance), as well as that their beneficial effects are often accompanied by a number of undesirable and serious possible side effects. And that when they are used, there is a great risk of permanent damage to health.  This therefore represents their main disadvantages and problem – high risk and likelihood that they can cause serious side effects and many health problems.

This is mainly because steroids have a strong effect on all androgen receptors in the body and in all tissues, not only in tissues where it is desired (anabolic effect on skeletal muscles and bones), but also on tissues where it is undesirable and harmful (causing androgenic harmful effects on the prostate, liver, skin, reproductive organs, brain, etc). 

Another serious problem with most steroids is that, like testosterone, they also can be extensively converted to DHT (dihydroxytestosterone) and estrogens in the body, which also contributes significantly to their possible unpleasant side effects. Among their less serious disadvantages could be the fact that many steroids require intramuscular injection (injection into a muscle) and would have no effect when used orally.

Research shows that some side effects of steroid use are reversible and others are not – they can mean permanent damage. For example, reversible side effects may include testicular atrophy (shrinkage), severely suppressed or completely stopped sperm production in men, acne, cysts, oily hair, increased blood pressure, “poor" cholesterol content, and / or increased aggression. Common irreversible injuries include for example androgenic alopecia (male pattern baldness), heart dysfunction, severe liver damage, or gynecomastia (breast growth in men). 

A list of possible harmful side effects of anabolic-androgenic steroids:

  • hepato-toxicity / high liver toxicity (oral steroids), possible severe liver damage, liver tumors and cysts
  • enlarged prostate, increased risk for prostate cancer
  • kidney problems or failure
  • increased blood pressure, numerous cardiovascular complications, increased risk of heart attack
  • increased low-density lipoprotein (LDL) cholesterol (the “bad" cholesterol)
  • decreased high-density lipoprotein (HDL) cholesterol (the “good" cholesterol)
  • suppressed or completely stopped sperm production in men, infertility, erectile dysfunction
  • strong suppression of endogenous testosterone production
  • testicular atrophy, testicular cancer
  • gynecomastia (breast growth in men)
  • sharp rise in cortisol and estrogen levels
  • massive fluid retention
  • severe acne and cysts, oily hair
  • androgenic alopecia (male pattern baldness)
  • increased size of the climate and deepened voice in women
  • excessive body hair growth in women
  • menstrual irregularities in women
  • increased aggression, mood swings, delusions, depression
  • restlessness or/and sleep problems
  • dumbing, brain degradation, dementia

Advantages of SARMs over anabolic steroids

The goal in the development of SARMs was and is to create synthetic androgen receptor ligands (androgen receptor modulators) that will respond to the tissues that are the target of therapy (skeletal muscle, bone) in the same way as to testosterone; but they will not respond to other tissues where testosterone and androgens produce undesirable side effects (as little as possible, or ideally not at all). Thus, to create substances that will have the strongest possible anabolic effect where it is desired, but at the same time a possible minimum of androgenic effects where it is undesirable.

Thus, a key characteristic underlying the potential of SARMs is their tissue specificity and high selectivity. While steroid hormone replacement therapy may be associated with a high rate of adverse effects, in part due to widespread and non-specific AR activation in many different tissues, SARMs seek to circumvent these adverse effects as much as possible, and to act selectively and beneficially only in tissues where it is appropriate and desirable.

Therefore, most SARMs have a significantly higher (better) ratio of anabolic and androgenic effects than testosterone and steroids: While testosterone has a 1:1 ratio of anabolic and androgenic effects, for example SARM RAD140 has an incomparably better and safer ratio – up to 90 times stronger anabolic effects versus its possible androgenic effects (therefore its possible side androgenic side effects are essentially almost completely ruled out).

Another great advantage of most SARMs over steroids is that all SARMs are highly effective even when administered orally, and at the same time without serious harmful effects on the liver. (This is true for most SARMs, but there are exceptions, such as SARM MK-3984, which was excluded from studies and did not continue to develop due to an increase in liver enzymes to more than three times the upper limit of normal found with its use.) Because SARMs, unlike oral steroids, are not methylated and are therefore not toxic and dangerous to the liver in this way. While most anabolic steroids are either not active and effective when administered orally (must be injected intramuscularly), or anabolic steroids that are active and effective when administered orally tend to cause dose-dependent loading and hepatic adverse effects,  which can damage the liver very seriously if used excessively. 

In addition, SARMs are not metabolized to dihydrotestosterone (DHT), do not aromatize to estrogens, nor do not cause significantly increased water retention in the body. SARMs also do not have such a strong and rapid effect on reducing and suppressing the production of own testosterone in the body. At the same time, if such a reduction in endogenous testosterone production occurs with the use of SARMs, its recovery after use and discontinuation of SARMs is significantly easier, faster and more likely than with the suppression of endogenous testosterone production by anabolic steroids. Therefore, research on SARMs certainly represents another significant step towards a safer class of androgenic drugs.

A list of advantages and benefits of SARMs over anabolic-androgenic steroids:

  • Effectiveness of SARMs to support the growth, development and maintenance of muscle mass and bone density in this regard is comparable to the effectiveness of anabolic-androgenic steroids, but SARMs present significantly fewer possible and significantly less serious side effects and health problems or risks, that the use of anabolic-androgenic steroids can and often does cause
  • SARMs can be highly selective and targeted to specific tissues, which means that they can have a positive effect where desired (strong anabolic effect in skeletal muscle and bone), and as little as possible where it is undesirable or harmful (prostate, liver, skin etc)
  • Most SARMs have a significantly higher (better) ratio of anabolic and androgenic effects than testosterone and steroids, for example, while testosterone has a 1: 1 ratio of anabolic and androgenic effects, SARM RAD140 has an incomparably better and safer ratio of 90: 1 (up to 90-times stronger anabolic effects compared to possible androgenic effects)
  • SARMs do not have such a strong and rapid effect on reducing and suppressing the production of endogenous testosterone in the body, and if reduction in endogenous testosterone production occurs with the use of SARMs, its recovery after use and discontinuation of SARMs is significantly easier, faster and more likely against anabolic steroids
  • SARMs are highly effective even when administered orally (no muscle injections are required), and at the same time without serious harmful effects on the liver, because SARMs are not methylated and therefore not toxic to the liver in this way
  • SARMs can help build higher quality, more stable and longer lasting muscle gains than steroids
  • SARMs are not metabolized to dihydrotestosterone (DHT), and do not aromatize to estrogens
  • SARMs do not cause significantly increased water retention in the body
  • SARMs do not cause acne, cysts or oily hair and skin
  • SARMs do not cause kidney problems or failure

SARMs vs. Anabolic steroids comparison

The biggest different and advantage of SARMs over anabolic steroids is that SARMs have significantly fewer possible and less serious side effects, health problems and risks. These advantages of SARMs are due to the fact that SARMs are highly selective – they act preferentially on androgen receptors where desired – ie in muscles and bones and at the same time act minimally or not at all on tissues and organs where it would be undesirable and harmful (prostate , liver, kidneys, skin, genitals, etc.)

SARMs vs. Steroids table – a comparison of harmful and adverse effects:

Possible harmful / adverse effects or health risks probability with  >>> SARMs: Steroids:
Overall heavy health damage risk NO HIGH!
High liver toxicity – possible severe liver damage, tumors and cysts NO HIGH!
(oral AAS)
Enlarged prostate, increased risk for prostate cancer NO HIGH!
Kidney problems or failure NO YES
Increased blood pressure, cardiovascular complications, increased risk of heart attack NO YES
Increased low-density lipoprotein (LDL) cholesterol (the “bad" cholesterol) NO YES
Decreased high-density lipoprotein (HDL) cholesterol (the “good" cholesterol) NO YES
Extremely suppressed or completely stopped sperm production in men LOW HIGH!
Infertility and impotence NO HIGH!
Enerectile dysfunction NO YES
Strong suppression of endogenous testosterone production MID HIGH!
Testicular atrophy, testicular cancer NO HIGH!
Aromatization NO YES
Sharp rise in cortisol and estrogen levels NO YES
Gynecomastia (breast growth in men) NO HIGH!
Massive fluid retention NO HIGH!
Severe acne and cysts NO HIGH!
Oil skin, oily hair, very strong deterioration of skin quality NO HIGH!
Hair lost and Androgenic alopecia (male pattern baldness) NO HIGH!
Androgenic mutations, deepening of the voice NO YES
Increased size of the climate and deepened voice in women NO YES
Excessive body hair growth in women NO YES
Menstrual irregularities in women MID YES
Increased aggression, mood swings, delusions, depression NO HIGH!
Mental disorders NO YES
Restlessness or/and sleep problems NO YES
Excessive sweating NO YES
Dumbing, brain degradation, dementia NO YES

SARMs and bone density

Bone is a living tissue that is constantly decomposing (bone resorption) and at the same time regenerating (bone formation) by osteoclasts and osteoblasts. Androgenic ligands affect a bone mineral density (BMD, the amount of bone minerals in bone tissue) by altering the total osteoblastic activity and osteoclastic activity that result from changes in the total number of each cell type and the individual functional capacity of the cell. These actions are mediated directly by the androgen receptor and by paracrine and autocrine action.

Androgens have been shown to have the ability to slow the bone remodeling cycle and tilt the focal balance of the cycle toward bone formation. Androgen deprivation is thought to increase the rate of bone remodeling by removing the limiting effects on osteoblastogenesis and osteoclastogenesis. Androgens also have dual effects on the viability of mature bone cells, with antiapoptotic effects on osteoblasts and osteoclasts and proapoptotic effects on osteoclasts. Dihydroxytestosterone also stimulates osteoblast proliferation and has a suppressive effect on osteoclast differentiation. The ability of SARMs to increase bone density in animal models suggests that they may provide a unique dual approach to the treatment of osteoporosis.

Science, research and therapeutic potential of SARMs

SARMs offer many possibilities for clinical applications and possible uses in the future with the promise of safe use, in the treatment of serious diseases and conditions such as cachexia, benign prostatic hyperplasia, hypogonadism, breast and prostate cancer and more. Depending on their chemical structure, SARMs can act as agonists, antagonists, partial agonists, or partial antagonists of the androgen receptors within different tissues, which represents their enormous advantages over conventional androgens. In addition, to date, SARMs have been shown to be well tolerated, easily administered orally, and generally lack significant side effects that are often a problem with many drugs, which may only further increase the future utility of SARMs. Is therefore logical that SARMs are the subject of research by many scientists and extensive research around the world. Their development has therefore progressed significantly in recent years and a number of scientific and clinical studies have been conducted on SARMs, and further developments are ongoing.

Muscle-wasting disorders

In healthy individuals, muscles are in equilibrium between their degradation and synthesis, and any change in the rate of degradation or protein synthesis may favor muscle atrophy (loss of muscle mass, catabolism) or hypertrophy (muscle cell growth). Statistics show that adults over the age of 40 lose about 1% of their muscle mass each year. Age-related muscle loss or sarcopenia (sarcopenia is a progressive, generalized loss of muscle mass, muscle strength, and muscle function) and muscle loss due to cancer (cancer cachexia) are two serious disorders of muscle loss. Patients with advanced cancer lose muscle mass rapidly, and studies have shown that muscle mass directly correlates with survival in cancer patients. 

Androgens are highly effective in building and maintaining skeletal muscle and, due to their anabolic effects on muscles, are often used to treat cancer cachexia and sarcopenia. Androgens increase the cross-sectional areas of both type I and type II muscle fibers in a dose-dependent manner, but do not change the absolute number or ratio of type I and type II fibers. The androgen-induced increase in muscle fiber cross-section correlated with an increase in the number of myonuclear cells and the number of satellite cells. Which means that androgen increases the number of satellite cells, which leads to muscle fiber hypertrophy and increases the number of myonuclear cells. 

However, a serious problem with androgens is their current androgenic side effects on other tissues. SARMs are therefore particularly interesting, promising and important in this regard due to their high tissue selectivity and potential to provide comparable positive therapeutic effects and muscle gains, but at the same time with significantly reduced possible harmful effects on other tissues. SARMs have been shown to be effective in eliminating and reversing several preclinical models of muscle loss, including glucocorticoid-mediated muscle atrophy. Numerous scientific studies have clearly shown that SARMs promote tissue anabolism and muscle protein synthesis. SARMs have the ability to reverse and prevent iatrogenic and disease-induced catabolism with minimal or beneficial antagonistic effects on other androgenic tissues.

Muscular dystrophies

Another group of diseases in which SARMs can be very useful in the treatment are muscular dystrophies. Duchenne muscular dystrophy (DMD) is a genetic disorder that arises due to mutations in the cytoskeletal protein dystrophin. Boys with DMD suffer from progressive muscle loss and weakness, and before reaching puberty, this insidious disease and loss of muscle function often leads them to a wheelchair. In addition, they suffer from heart and respiratory failures due to weakness of the heart and lungs, leading to premature death. 

Studies using Oxandrolone in boys with DMD have shown muscle growth and increased protein synthesis, but the hepatotoxicity of this steroid and genital side effects have been serious barriers to such treatment. 

One of the very promising strategies proposed to combat DMD is the use of SARMs, either alone or in combination with other exon-skipping drugs, or with other strategies such as myostatin inhibitors (e.g. Follistatin-344 or ACE-031). SARMs administered to patients with DMD have the potential to cause an increase in muscle mass and protein synthesis comparable to the level observed with oxandrolone, but without its undesirable side effects. Any SARM should show broad tissue selectivity and a perfect safety profile in children with DMD.

Osteoporosis 

Osteoporosis (thinning of the bone) is a disease of bone metabolism, which is manifested by a decrease in the amount of bone mass and disorders of bone microarchitecture, which leads to a weakening of the overall strength of the bone and thus to their increased fragility and fragility. SARMs not only have strong abilities to increase protein synthesis and stimulate the growth and maintenance of muscle mass, but they can also have a positive effect on mineralization and increase bone density and strength, as clearly demonstrated by several studies in animal models.

In preclinical models, SARMs have been shown not only to prevent bone loss in castrated male rats and ovariectomized female rats, but also to increase bone strength (meaning an increase in bone density). Under these experimental conditions, they also increased the mineral density of cortical and trabecular bones above baseline. Or, SARM BA321, which binds to both androgen receptors (ARs) and estrogen receptors (ERs) without androgenic effects, was able to completely restore bone loss in orchidectomy mice.

At present, osteoporosis in humans is primarily treated with anti-resorptive agents, which prevent further bone breakdown in the body. Anti-resorptives potentially prevent further bone turnover, but will not be able to increase bone mass. However, SARMs have the unique potential to provide a complete dual approach to the treatment of osteoporosis, i. not only do they effectively prevent further thinning of the bones, but they can also effectively renew and increase bone mass.

Benign prostatic hyperplasia (BPH)

In the prostate, testosterone rapidly converts to dihydroxytestosterone (DHT) by the action of 5α-reductase type 2. This conversion to DHT enhances the action of testosterone 3-5 times, due to the significantly higher binding affinity of DHT (compared to testosterone) to the androgen receptor. DHT plays a crucial role in determining prostate size before and during adulthood and is considered essential for the development of benign prostatic hyperplasia (BPH), which occurs in 50% of men over the age of 50 and up to 90% of men over the age of 80. The major problem associated with BPH is lower urinary tract symptoms (LUTS). 

Much evidence suggests the importance of DHT in the development of BPP (e.g., BPH does not develop in men with 5α-reductase type 2 mutations, or in men with very low androgen levels due to hypogonadism associated with hypopituitarism). Clinical treatment with BPH with a type 2a-reductase inhibitor (e.g., Finasteride or Dutasteride) induces epithelial cell apoptosis, which in turn significantly reduces prostate volume. Therefore, testosterone supplementation in older men raises concerns about accelerating BPH. The role of age-related changes in the intraprostatic hormonal environment in the development of BPH has recently been investigated. Despite a decrease in testosterone and intraprostatic production of DHT associated with aging, an increased estradiol-DHT ratio was found in the transient zone of human prostate aging. Therefore, this relative estrogen-dominant state is also thought to be relevant for the development of BPH. In addition, scientific studies have found that estradiol is able to induce precancerous lesions and prostate cancer in aging dogs.

SARMs can be very attractive for the treatment of BPH because they have exceptional abilities to act as agonists, antagonists, partial agonists, or partial antagonists of the androgen receptors within different tissues. For example, one scientific study compared the use of flutamide with SARM S-40542 in a rat model of BPH: Both substances similarly reduced prostate weight in a dose-dependent manner, but S-40542 had a weaker effect on levator ani muscle than flutamide. [In addition, S-40542 showed no effect on testosterone or luteinizing hormone (LH) levels, both of which were elevated by flutamide. 

In another study, the researchers compared SARM S-1 and S-4 with finasteride and hydroxyflutamide in the treatment of BPH in a rat model. Both finasteride and SARM S-1 selectively reduced prostate weight to a similar extent without altering levator ani muscle or plasma levels of testosterone, follicle stimulating hormone (FSH) or LH, all of which were altered by hydroxyflutamide treatment. SARMs S-1 and S-4 slightly reduced 5-alpha-reductase levels, suggesting that they reduced prostate size by a mechanism other than finasteride. These results increase the possibility of using SARMs as monotherapy for the treatment of BPH with minimal side effects.

Prostate cancer

SARMs also have the potential to be useful in the treatment of prostate cancer. A scientific study in mice showed that SARM FL442 achieved high tissue concentrations in the prostate and acted as an androgen receptor antagonist in prostate cancer (PCa) cell models with efficacy comparable to that of enzalutamide, an antiandrogen used in the treatment of PCa castration resistance. In particular, SARM FL442 maintained the ability to prevent cell proliferation, even in cell lines with AR mutations that conferred resistance to enzalutamide.

Another scientific study focused on SARM MK-4541, which induces Caspase-3 activity and apoptosis in androgen independent AR positive prostate cancer cell lines while paring AR- and AR+ non-prostate cancer cells. Administration of SARM MK-4541 has been shown to reduce plasma testosterone levels, likely through AR-mediated negative feedback signaling through the hypothalamic-pituitary-gonadal axis.

These results suggest a significant potential for SARMs in the treatment of hormone ablation-resistant disease through the activation of AR-induced expression profiles that are toxic to cancer cells while avoiding the negative effects of traditional antiandrogen therapies.

Breast Cancer

Although androgens are considered a risk factor for prostate cancer, they are recommended for the treatment of breast cancer. Prior to the discovery of SERMs and aromatase inhibitors, steroidal androgens such as medroxyprogesterone and fluoxymesterone were used to treat breast cancer. AR expression in breast cancer was consistently correlated with better disease-free survival and overall survival. In addition, the combined expression of AR with steroidogenic enzymes, which leads to increased androgen synthesis, has been shown to be extremely beneficial in breast cancer. However, these steroidal androgens, as mentioned above, have caused virilization, which is a very serious problem.

SARMs represent another option for safe and effective treatment for women with breast cancer. Although the mechanism underlying the role of AR in breast cancer is not fully elucidated, experimental evidence suggests that AR inhibits ER function to inhibit the growth of ER-positive breast cancers. Up to 85% of ER positive breast cancers and 95% of ER negative breast cancers express AR. Androgen receptors in breast cancer likely confer survival advantage by modulating ER signaling, which may reduce the risk of metastasis and aggressive disease.

Alzheimer’s disease

Hypogonadal men suffering from testosterone deficiency demonstrate a decline in various cognitive processes, including episodic memory, working memory, processing speed, visual spatial processing, and powerful functions. These functions are partially regulated by areas of the brain that are modulated by AR. The researchers conducted a subanalysis of the Baltimore Longitudinal Study of Aging, which included 407 men without dementia, who were followed for an average of 9.7 years. Study subjects underwent medical, physiological, and neuropsychological evaluations, as well as laboratory tests for total testosterone and steroid hormone binding globulin. The free testosterone index was calculated based on total levels of testosterone and steroid hormone binding globulin. The results showed that a higher free testosterone index was associated with better visual and verbal memory scores, visual spatial function, visual-motor scanning, and reduced rate of longitudinal visual memory decline. 

Testosterone depletion and deficiency are considered a significant risk factor for Alzheimer’s disease, and circulating testosterone levels are inversely correlated with amyloid β (Aβ) levels in the brains of older men. Androgens suppress Aβ accumulation by upregulating the expression of neprilysin, which degrades amyloid. Given the important positive effects of testosterone on cognition, we can hypothesize that SARMs may also be useful in the treatment of cognitive disorders such as Alzheimer’s disease. For example, Akita Kazumasa et al. demonstrated that SARM NEP28 increases the activity of neprilysin in addition to having systemic anabolic effects with reduced androgenic effects. Therefore, further progress and research in the field of SARMs also gives new hope to patients with Alzheimer’s disease, for whom SARMs may be very useful in the future.

SARMs benefits, effects and results

  • SARMs can be highly selective and targeted to specific tissues, which means that they can have a positive effect where desired (strong anabolic effect in skeletal muscle and bone), and as little as possible where it is undesirable or harmful (prostate, liver, skin etc)
  • SARMs have strong anabolic properties and the ability to induce a rapid increase in protein synthesis and hypertrophy in muscle tissues (growth and increase in the volume of skeletal muscle cells), they allow to achieve rapid and massive growth of muscle mass
  • SARMs are also very effective in keeping muscle mass and can protect muscles from degradation because they have strong anti-catabolic effects
  • SARMs can be a great and many times safer alternative to androgens and anabolic steroids
  • SARMs have a minimum of possible adverse side effects compared to anabolic steroids, and a much better safety profile
  • SARMs can have a significantly higher (better) ratio of anabolic and androgenic effects than testosterone and steroids
  • SARMs are not metabolized to dihydrotestosterone (DHT), and do not aromatize to estrogens
  • SARMs can help build higher quality, more stable and longer lasting muscle gains than steroids
  • SARMs have a positive effect on increasing bone density and their mineralization
  • SARMs are highly effective even when administered orally (no muscle injections are required)
  • SARMs, based on current scientific knowledge do not have serious harmful effects on the liver, kidney and prostate
  • SARMs do not cause significantly increased water retention in the body, or do not cause acne, cysts or oily hair and skin
  • SARMs offer many possibilities for clinical applications and possible uses in the future with the promise of safe use, in the treatment of serious diseases and conditions
  • SARMs can act as agonists, antagonists, partial agonists, or partial antagonists of the androgen receptors within different tissues, which represents their enormous advantages over conventional androgens
  • SARMs can be very useful in the treatment of diseases related to muscle loss and wasting (age-related muscle loss, sarcopenia, cachexia, Duchenne muscular dystrophy) 
  • SARMs have the unique potential to provide a complete dual approach to the treatment of osteoporosis (effectively prevent further thinning of the bones and at the same time also effectively renew and increase bone mass)
  • Possibility of using SARMs as monotherapy for the treatment of benign prostatic hyperplasia (BPH) with minimal side effects
  • SARMs also have great potential to be useful in the treatment of prostate cancer
  • SARMs represent another option for safe and effective treatment for women with breast cancer
  • SARMs also can be useful for patients with Alzheimer’s disease in future

SARMs possible side effects, concerns

  • SARMs can suppress the body’s natural production of testosterone (but much milder and less severely than Anabolic androgenic steroids does). The probability and rate of reduction in testosterone production often depends directly on the dose and duration of use of SARMs, as well as on the particular type of SARM.
  • The large number of counterfeits on the market (which in fact do not contain SARMs at all), more than half of the alleged SARMs offered on the Internet are fake from fraudsters
  • Possible increased risk of heart attack or stroke in SARMs that lower high-density lipoprotein (HDL) cholesterol levels
  • For some SARMs, there are considerations or conjectures, that they would be potentially harmful to the liver (these are mainly SARMs RAD140 and YK11). To date, however, there are no clinical studies that can provide credible and relevant evidence
  • The long-term effects of SARM use have not been yet well tested

Important Notice

Please keep in mind that all our products, sarms and peptides are sold exclusively for scientific research purposes. They are not food or food supplements and should not be used for purposes other than those for which they are intended. Any non scientific research use is at your own risk.

Are SARMs harmful to the liver? Science Vs. rumors

Opinions differ as to whether or not non-steroidal SARMs are harmful to the liver (or their use poses a risk to the liver or not). While one group of people will claim that SARMs do not pose any risk and burden to the liver at all, the other group of people will claim that all SARMs are certainly or may be harmful to the liver. Many websites and people without knowledge of this issue will blindly or purposefully prefer the opinion of the first group (for example, especially fraudsters – counterfeit sellers who always write only for their benefit), on the contrary, enemies of SARMs, steroids and doping in general, will be for each price defend the opinion of the second group. 

We always try to give people serious, as relevant, truthful and accurate information as possible, from all the knowledge and resources available to us (regardless of whether they suit us more or less). So let’s try to find the truth based on an objective view and existing scientific knowledge about SARMs, or at least get as close to it as possible:

The arguments of many opponents of SARMs who claim that SARMs clearly pose a risk to the liver are often “water-based" and derived from the following logic: Since SARMs can provide similar positive effects as steroids (especially promoting massive muscle growth), it is logical that they must have similar side effects, and since oral steroids are hepatotoxic (highly harmful to the liver), certainly SARMs, which are their real and equally oral alternative, must also be significantly harmful to the liver. What is great stupidity and dullness, because oral steroids are toxic to the liver due to the fact that they are so-called alkylated (methylated). This is because clear steroids and testosterone, when taken orally, would be very strongly degraded and inactivated during the first pass through hepatic metabolism, and would not cause essentially any anabolic effects in the body. 17-a alkylation involves the addition of an alkyl group (methyl or ethyl) to the alpha position of the 17 carbon of the steroid backbone. The alkylation at this position prevents the major route of androgen deactivaton – oxidation to a 17-keto steroid – from taking place. This allows a large part of the steroid to avoid liver first pass metabolic degradation. While 17-alpha alkylation is a very effective way to make steroids effective even when administered orally, a serious problem is that it places a heavy burden on the liver and can cause very serious damage to the liver.

However, non-steroidal SARMs are not methylated, so it is absolute nonsense to suspect them of damaging the liver in a similar way to oral steroids (oxymetholone, methandrostenolone, androstanazole, and others). Or, in the end, many critics of SARMs will limit themselves to the fact that they have read somewhere that some coach or organization has said that SARMs seriously damage the liver, so it must then apply, and the matter is resolved and clear. 

Some other people refer to a scientific study in which (also) SARM Ostarine (MK-2866) was used, during which an increase in liver enzymes, which usually signal liver damage, to more than three times the upper limit was noted. The simplification and inaccurate interpretation of the results of this study is probably behind the birth of information and claims that have spread across the Internet and suggest that SARM Ostarine is harmful to the liver. Again, however, this is manipulated and untrue information, although it also refers to scientific sources and the study actually carried out, but its results have been distorted, cut out and misinterpreted. Let’s take a closer look at the aforementioned scientific study in which an excessive load or possible liver damage was found:

June 21, 2010 GTx, Inc. reported the results of clinical trials in which SARM Ostarine (GTx-024, MK-2866) and SARM MK-3984 were used and tested. The 12 week, randomized clinical trial evaluated Ostarine 3 mg and two doses of MK-3984 compared to placebo in 88 postmenopausal women. Total lean body weight was measured with DEXA at ​​baseline and after 12 weeks, and physical performance was assessed at the same interval with a bilateral leg press. SARM Ostarine increased lean body mass and leg pressure in a self-directed study evaluating Ostarine and another selective androgen receptor modulator, SARM MK-3984, in postmenopausal women. 

After 12 weeks of treatment, Ostarine and MK-3984 significantly increased overall lean body mass. Compared to placebo, mean differences from baseline in lean body mass were observed with an increase of 1.54 kg (p value <0.001) for both SARMs Ostarine 3 mg and 50 mg MK-3984 and an increase of 1.74 kg (p value < 0.001) for 125 mg MK-3984. Increases in thigh muscle volume as measured by MRI for Ostarine and MK-3984 were noted as early as week 4, with an effect lasting until the end of the study. Treatment with Ostarine and MK-3984 resulted in an increase in leg muscle strength. Mean leg muscle strength after 12 weeks in SARM Ostarine-treated subjects increased by 22 pounds from baseline. Ostarine and MK-3984 were tissue selective. Treatment in these women did not cause virilization because there was no change in sebaceous gland volume, sebum secretion rate, or hair follicle gene expression. In addition, Ostarine and MK-3984 did not stimulate endometrial proliferation, as measured by endometrial thickness. 

“This is Ostarine’s third clinical study to measure the endpoints of lean body weight and physical performance, and SARM Ostarine has consistently demonstrated her ability to increase muscle mass and strength. We also continue to enjoy Ostarine’s safety profile, “said Mitchell Steiner, CEO.

In terms of safety, 7 patients treated with SARM MK-3984 were excluded from the study due to an increase in liver enzymes more than three times the upper limit of normal, while patients treated with SARM Ostarine did not show any clinically relevant elevations in liver enzymes. Thus, the study concluded, in short, 12 weeks of treatment with Ostarine (3 mg) and MK-3984 had comparable efficacy on overall lean body mass, muscle strength, and tissue selectivity in postmenopausal women. And while SARM MK-3984 showed an increase in liver enzymes and therefore its further development was stopped, Ostarine was well tolerated, with no clinically significant increases in liver enzymes

The second case known to us, and it is also ever the first published report that deals exclusively with significant liver damage due to the “alleged" use of SARMs is case report “Drug-Induced Liver Injury Associated with Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033)", published in June 2020. This report mentions the case of a 52-year-old man who stated that he was taking two preparations containing SARMs, one of which was declared as RAD140 and the other a combination of RAD140 and LGD-4033. This man asked the hepatology clinic to evaluate his elevated liver enzymes and jaundice. According to his statement, about 4 months before that he started taking 20 mg of RAD-140 (which was supposed to be contained in the first preparation) daily for 4 weeks, and after stopping RAD140, he started taking 7.5 mg of RAD-140 and 5 mg of LGD-4033 (which should be included in the second preparation) daily for 3 weeks to build muscle. The total duration of use was 7 weeks. Shortly afterwards, he developed jaundice, upper right quadrant pain, itching, and diarrhea. He also said that he drinks bourbon and beer daily and uses marijuana.

The report evaluates and presents the results of Liver Biopsy (Liver biopsy is a medical examination that is performed to help diagnose liver disease, to assess the severity of liver damage). In summary, the results are reported to show diffuse centrilobular canalicular cholestasis, a marked ductular response, and mild lobular inflammation with a rare necrotizing epithelioid granuloma suggesting liver damage due of use of mentioned SARMs. At the same time, liver enzymes are reported to return to normal approximately 3 months after the patient discontinued both preparations.

However. The credibility and relevance of the claims or unequivocal verdict that the liver damage found in this person was actually caused by the use of SARMs (or just SARMs), are challenged by several significant doubts. It is not possible to draw a relevant and reliable conclusion, which is based on a number of unverified important input data, where their only source is the data reported by this patient, and which have not been scientifically reviewed, verified and monitored at all (as must be the case in clinical trials). And just rely on the fact that this information and facts provided to patients were hopefully true, correct and accurate.

What if, for example, this man concealed the fact that he was taking anabolic steroids with SARMs? What bodybuilders who experiment with using SARMs to increase muscle mass, on bodybuilding forums often report, that they do – that they combine SARMs and steroids, in the expectation that this will lead to even greater muscle gain, or that SARMs have the ability to eliminate the negative effects of steroids to some extent if taken at the same time. Or what if this man used counterfeits from fraudsters, which instead of SARMs contained mostly anabolic steroids, or even no SARMs at all? No one researched and analyzed the substances (preparations) that the man had used – what their composition and content were in fact, which may not at all coincide with what was claimed on their packaging, that it is really in the content. SARMs are significantly more expensive compounds than anabolic steroids, which are cheap, which can be abused by doubtful people and characterless fraudsters: In order to have minimal costs, they can incorporate cheap anabolic steroids into content instead of real SARMs, which reduces their costs to a minimum, but also ensures that the inexperienced customer will see some of the effects he is targeting and expecting – ie. anabolic effects. 

In both cases, it would completely change the true origin and main source of the liver damage found, that may have been caused by anabolic steroids, not by non-steroidal SARMs. In addition, regular alcohol consumption may have predisposed the patient to liver damage.

Steroidal SARM YK11 concern: Some scientists suggest that the use of YK-11 may have potential toxic effects on the liver. The reason is its chemical structure which is derived from 5-α-dihydrotestosterone (DHT) and also similar to steroids which are considered toxic to the liver. Due to the 4 methylated groups present in the structure of steroidal SARM YK11 partial harmfulness to the liver can be really expected. To date, clinical studies with SARM YK11 in humans have not been performed, thus, the answers to these questions regarding the safety of SARM YK11 have not yet been reliably given (the only source of information so far is only the experience of experimental users published and shared on various bodybuilding forums).

To date, we don’t have any reliable, relevant and credibly proven information that any current non-steroidal SARMs that continues or are in our offer has shown a significant negative effect on the liver in clinical and scientific studies. (And if we will have newer and more accurate knowledge, we will of course update our content.) Therefore, based on current and actual scientific knowledge, we consider current non-steroidal SARMs in safe dosing and proper use to be safe and without significant risk to the liver. Of course, with the necessary caution observed. However, this also does not guarantee that liver damage cannot be detected in some SARMs in the future.

Furthermore, it should also be emphasized that if the recommended and safe dose of SARMs is exceeded, an increased risk of possible side effects can be expected, in particular a more pronounced suppression of endogenous testosterone production. The long-term effects of taking SARMs have also not been tested long enough, so it cannot be ruled out that new knowledge about possible side effects may emerge in the future. Please also keep in mind that all our products, sarms and peptides are sold exclusively for scientific research purposes. They are not food or food supplements and should not be used for purposes other than those for which they are intended. Any non scientific research use is at your own risk.

SARMs FAQ and safety


Important Notice:  Please keep in mind that all our products, sarms and peptides are sold exclusively for scientific research purposes. They are not food supplements or food and should not be used for purposes other than those for which they are intended. Any non scientific research use is at your own risk.


What are SARMs?

SARMs – Selective androgen receptor modulators are synthetic compounds which belong to the class of androgen receptor ligands and bind with high affinity to androgen receptors (AR) in targeted and desired tissues.

What is the main effect of SARMs?

The main effects of SARMs are mainly their strong anabolic properties and their ability to induce a rapid increase in protein synthesis and hypertrophy in muscle tissue (growth and increase in the volume of skeletal muscle cells).

What are the positive effects and benefits of SARMs?

SARMs offer many benefits and usable positive effects with the current possible minimum of undesirable side effects: SARMs have a strong anabolic effect on skeletal muscle and bone, thus supporting the growth of muscle mass and increasing bone density and mineralization, while being able to protect existing muscle mass from catabolism. SARMs can act as agonists, antagonists, partial agonists or partial antagonists of androgen receptors in various tissues, thanks to this unique property they can be very useful in the future in the treatment of several serious diseases, such as diseases related to muscle loss (sarcopenia, cachexia, DMD), in the treatment of osteoporosis, benign prostatic hyperplasia, prostate cancer, breast cancer in women or patients with Alzheimer’s disease. In addition, SARMs are highly effective when administered orally (no muscle injections are required). 

At the same time, however, SARMs have a much better safety profile and do not cause most of the serious harmful side effects of androgen and steroid use: SARMs do not metabolize to dihydrotestosterone (DHT) and do not aromatize to estrogens, do not have strong adverse effects on liver, kidney and prostate, do not cause water retention in the body, nor do they cause acne, cysts, oily skin and hair and other problems related to steroid use.

Are SARMs safe? Are SARMs effective? 

Based on current scientific knowledge and scientific and clinical studies performed to date, it can be said that ongoing non-steroidal SARMs are highly effective and at the same time relatively safe at safe dosing. This has been confirmed by several human clinical studies performed, for example a small summary of such a study: “The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men" summarizes a placebo-controlled study in which 76 healthy men (21-50 years) were randomized to placebo or 0.1, 0.3 or 1.0 mg SARM LGD-4033 daily for 21 days. Blood counts, chemical analysis, lipids, prostate specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength were measured during and 5 weeks after the intervention. 

SARM LGD-4033 was well tolerated. There were no serious adverse events related to the use of SARM. Hemoglobin, prostate specific antigen, aspartate aminotransferase, alanine aminotransferase or QT intervals were not significantly altered at any dose. LGD-4033 had a long elimination half-life and dose-proportional accumulation after repeated administration. Administration of LGD-4033 has been associated with suppression of total testosterone, sex hormone binding globulin, high density lipoprotein cholesterol, and dose-dependent triglyceride levels. Follicle stimulating hormone and free testosterone showed significant suppression only at the 1.0 mg dose. Muscle mass increased in a dose-dependent manner. Hormone and lipid levels returned to baseline after treatment. LGD-4033 was safe, had a favorable pharmacokinetic profile, and increased lean muscle mass even during this short period without altering prostate-specific antigen.

Of course, it cannot be completely ruled out that new knowledge on possible side effects may emerge in the future. Also an exception is the steroidal SARM YK11, which is expected to have some increased liver burden and has not been clinically tested in humans at all, so it cannot be considered safe.

Are SARMs safer than anabolic steroids? 

Compared to competing AS ligands (classical androgens testosterone, DHT and their synthetic analogues – anabolic steroids), non-steroidal SARMs have a much better safety profile and do not cause most of their serious harmful side effects.

This is mainly due to their high selectivity – the ability to act on androgen receptors preferentially in tissues where it is desired and as little as possible in tissues where it is undesirable. Also, unlike oral (17-alpha alkylated (17aa)) steroids, non-steroidal SARMs are not methylated and therefore not toxic to the liver in this way.

To date, clinical research and studies have found no serious side effects at safe and appropriate dosing in SARMs whose research and development is ongoing. Therefore, based on the current knowledge that research has today regarding SARMs, we can consider non-steroidal SARMs at a safe dosage as a relatively safe and many times safer alternative to anabolic steroids. However, it should also be emphasized that, if the recommended and safe dosage is exceeded, a significant increase in their possible side effects can be expected, in particular a more pronounced suppression of endogenous testosterone production. The long-term effects of taking SARMs have also not been tested long enough, so it cannot be ruled out that new knowledge about possible side effects may emerge in the future.

What are side effects of SARMs?

The most common and common side effect with SARMs is a dose- and duration-dependent reduction in the body’s natural production of testosterone (but milder and less severe than with anabolic androgenic steroids). And with SARMs that lower high-density ipoprotein (HDL) cholesterol, there is an increased risk of heart attack.

To date, clinical research and studies have not identified any other serious side effects at safe and appropriate dosing in SARMs, which have been clinically tested in humans and whose research and development is ongoing. However, the long-term effects of taking SARMs have also not been tested long enough, so it cannot be completely ruled out that some other side effects may occur in the future.

Do SARMs reduce the production of testosterone in the body?

Yes. Most SARMs can cause and also cause a dose-dependent decrease in the body’s natural production of testosterone. However, at safe dosing, SARMs have a significantly milder and less severe impact on testosterone production than anabolic steroids, while full recovery of testosterone production is much faster, less complicated, and more likely than steroids after discontinuation. The likelihood and rate of reduction in testosterone production often depends directly on the dose and duration of SARMs use, as well as on the particular type of SARM.

Are SARMs harmful to the liver? Do SARMs damage your liver?

To date, we don’t have any credible information that any non-steroidal SARMs that continues or are in our offer has shown a significant negative effect on the liver in clinical and scientific studies (that have performed all the necessary procedures and conditions for credible and objective results). Therefore, based on current scientific knowledge, we consider non-steroidal SARMs in safe dosing and proper use to be safe and without significant risk to the liver. Of course, with the necessary caution observed. However, this also does not guarantee that liver damage cannot be detected in some SARMs in the future.

Steroidal SARM YK11 liver concern: Some scientists suggest that the use of YK-11 may have potential toxic effects on the liver. The reason is its chemical structure which is derived from 5-α-dihydrotestosterone (DHT) and also similar to steroids which are considered toxic to the liver. Due to the 4 methylated groups present in the structure of steroidal SARM YK11 partial harmfulness to the liver can be really expected. To date, clinical studies with SARM YK11 in humans have not been performed, thus, the answers to these questions regarding the safety of SARM YK11 have not yet been reliably given (the only source of information so far is only the experience of experimental users published and shared on various bodybuilding forums).

Does Ostarine affect liver / is Ostarine harmful to the liver?

Inaccurate interpretation of the results of conducted clinical study is probably behind the birth of information and claims that have spread across the Internet and suggest that non-steroidal SARM Ostarine is harmful to the liver: GTx, Inc. reported the results of clinical trials in which SARM Ostarine (GTx-024, MK-2866) and SARM MK-3984 were used and tested. While SARM MK-3984 showed an increase in liver enzymes and therefore its further development was stopped, Ostarine was well tolerated, with no clinically significant increases in liver enzymes. However, it can be assumed that someone combined the results of the whole study into the false conclusion that Ostarine proved to be harmful to the liver in this study.

Does RAD 140 affect liver?

Although some people believe or argue that non-steroidal SARM RAD140 has a significant negative effect on the liver, to date, we have no credible information that SARM RAD140 has shown a significant adverse effect on the liver in any conducted clinical and scientific studies (that have performed all the necessary procedures and conditions for credible and objective results). But it cannot be completely ruled out that new knowledge on possible side effects may emerge in the future.

Is Rad 140 Safe?

Based on current scientific knowledge and scientific and clinical studies performed to date, SARM RAD140 seems to be at safe dosing relatively safe, and no serious side effects were found. Of course, it cannot be completely ruled out that new knowledge on possible side effects may emerge in the future. Also, if the recommended and safe dosage of RAD140 is exceeded, the likelihood that more serious side effects could occur also increases. 

Is LGD-4033 Safe? How safe is LGD-4033?

Based on current scientific knowledge and scientific and clinical studies performed to date, non-steroidal SARM LGD-4033 seems to be at safe dosing relatively safe, and no serious side effects were found. For example, performed clinical study “The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men" summarizes a placebo-controlled study in which 76 healthy men (21-50 years) were randomized to placebo or 0.1, 0.3 or 1.0 mg LGD-4033 daily for 21 days. Blood counts, chemical analysis, lipids, prostate specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength were measured during and 5 weeks after the intervention. LGD-4033 was well tolerated. There were no serious adverse events related to the use of LGD-4033. 

Hemoglobin, prostate specific antigen, aspartate aminotransferase, alanine aminotransferase or QT intervals were not significantly altered at any dose. Sarm LGD-4033 had a long elimination half-life and dose-proportional accumulation after repeated administration. Administration of LGD-4033 has been associated with suppression of total testosterone, sex hormone binding globulin, high density lipoprotein cholesterol, and dose-dependent triglyceride levels. Follicle stimulating hormone and free testosterone showed significant suppression only at the 1.0 mg dose. Muscle mass increased in a dose-dependent manner. Hormone and lipid levels returned to baseline after treatment. Sarm LGD-4033 was safe, had a favorable pharmacokinetic profile, and increased lean muscle mass even during this short period without altering prostate-specific antigen. Of course, it cannot be completely ruled out that new knowledge on possible side effects may emerge in the future. Also, if the recommended and safe dosage of LGD-4033 is exceeded, the likelihood that more serious side effects could occur also increases.

How long does it take for SARMs to kick in?

SARMs have a relatively short biological half-life, approximately between 12 and 36 hours, and begin to act and work rapidly in the body after use. Therefore, most users can notice the first visible changes and improvements caused by the use of sarms after the first 2-3 days (in the form of increased strength, endurance and performance, and subsequent days then also in the form of new muscle gains).

Should SARMs be taken with or without food? Can you take SARMs on an empty stomach?

It is best to take SARMs with food (and if you plan a physical workout on a given day, at least 45 minutes before such workouts). With food, sarms will absorb more steadily and at the same time are less likely to get stomach upset. However, even if you take sarms on an empty stomach, they should still be highly effective.

Do SARMs speed up recovery?

Yes, sarms (like testosterone and its derivatives, steroids) significantly improve and accelerate muscle recovery after strenuous training or great physical exertion, and help achieve better regeneration. Men suffering from low testosterone levels and general fatigue may also notice a significant increase in energy and vitality when taking sarms.

Does SARMs cause hair loss?

It depends on the specific type of SARMs. While some sarms can prevent hair loss and have a positive effect against baldness (androgenic alopecia), some sarms can cause hair loss. DHT (5-α-dihydrotestosterone) is the main negative factor and most often responsible for hair loss and baldness in men. 

For example, sarm Andarine S-4 can act as an AR antagonist in the prostate or hair roots, thus protecting the prostate or hair roots from the harmful effects of DHT. Thus, Andarine can prevent excessive hair loss by eliminating the harmful effects of DHT on the hair and preventing the development of androgenic alopecia (permanent hair loss – balding in men).

While most sarms will not have a significant overall effect on hair loss, there are also SARMs that are likely to have a negative effect on hair and hair loss. It is mainly a steroidal SARM YK11, whose chemical structure is derived and very similar to DHT, thanks to which it can have similar negative effects on hair as DHT. Users of sarms report the most common hair loss most often in this sarm, YK11 (in other sarms, cases where the user reported significantly worsened hair loss are relatively rare). It is certainly worth noting that most users who confirmed increased hair loss while taking YK11 also reported that these negative effects disappeared after stopping YK11, and the condition of their hair returned to normal and the hair where they lost it began. grow again.

We can also assume that the significant and lasting effect on hair loss of sarms that can cause them will also be significantly affected by their doses and duration of use (overdoses will have a significantly higher probability and effect on hair loss, as well as too much long use).

How long does Ostarine stay in your system? What is the half-life of Ostarine?

Sarm Ostarine (MK-2866) has prolonged half-life of 24 hours. This means that the amount of Ostarine in the average person’s system should be halved every day until it disintegrates exponentially and is cleared from the body completely.

How long does MK 677 stay in your system? What is the half-life of Ibutamoren?

Ibutamoren (MK-677) is not a SARM, it is a selective non-peptide Ghrelin receptor agonist, and a growth hormone secretagogue with a half-life of approximately 4-6 hours, but human IGF-1 levels remain elevated at a single dose for up to 24 hours.

Are SARMs legal?

If you purchase SARMs for research purposes, this purchase (and sale) is legal in most European countries and the United States. These are neither nutritional supplements nor food, but substances intended and sold for research. Any use outside of scientific research is at your own risk

Are SARMs banned in sports?

Yes, SARMs are banned in sports. SARMs were added to the WADA (World Anti-Doping Agency) Prohibited List in 2008, and to this day, all SARMs continue to be banned by all major sports organizations.

The Most Popular SARMS quick review

Among the best known, most popular and also the most researched SARMs are certainly the LGD-4033 and Ostarine (MK-2866). Their strong anabolic properties, high efficiency and current good safety profile make them favorites among SARMs. Newer SARMs (which were developed much later) and are now highly popular and often discussed include certainly RAD140 and the steroidal SARM YK11 derived from the chemical structure of DHT. Many people also mistake Ibutamoren MK-677, SR9009 or GW1516 among SARMs, but they are certainly not SARMs, do not act on the androgen receptor and mediate their different effects in a different way than SARMs.

SARM LGD-4033 (LIGANDROL)

SARM LGD-4033 (LIGANDROL) LGD-4033 (Ligandrol, or also known as Anabolicum) is sure one of the most effective and powerful SARMs, with strong anabolic properties. Clinical studies performed in humans have clearly confirmed the strong anabolic properties of LGD-4033 and its unique ability to effectively stimulate muscle growth as well as significantly increase strength. 

A common side effect of sarm LGD-4033 is mild to moderate suppression of endogenous testosterone production in the body (both, total and free testosterone), which is still significantly weaker and less severe than with anabolic steroids. At the same time, recovery of testosterone after the end of the use of LGD-4033 is significantly easier, simpler and safer than with the use of testosterone or its synthetic derivatives (AAS). In one of the clinical studies performed, total testosterone decreased by more than 50% in test subjects, but at the same time, its levels returned to normal within 56 days after discontinuation of LGD-4033 without the use of PCT (post-cycle therapy). 

LGD-4033 is highly effective from small doses. At a dose of only 1 mg LGD-4033 per day and for a period of 21 days, 116 volunteers tested showed a significant improvement in muscle mass and strength, while reducing the percentage of body fat. In another test, even a higher dose of 22 mg LGD-4033 per day for several weeks did not cause any significant adverse effects or health problems. SARM LGD-4033 can therefore be considered a strong, high-anabolic SARM with a sufficiently safe profile.

SARM OSTARINE (MK-2866)

SARM OSTARINE (MK-2866)Ostarine (also marked as MK-2866, Enobosarm and GTx-024) is a non-steroidal selective androgen receptor modulator primarily developed for the treatment of conditions such as muscle loss and osteoporosis (bone thinning). In 2006, a 12-week double-blind, placebo-controlled phase II clinical study examined the effects of Ostarine on 120 healthy elderly men tested over the age of 60 years and in postmenopausal women. Administration of ostarine resulted in a dose-dependent increase in total net body weight and a statistically and clinically significant increase in muscle mass (P <0.001, 3 mg versus placebo) as well as a significant improvement in physical function (P = 0.013, 3 mg versus placebo). At the same time, SARM Ostarine was well tolerated throughout the period of use. The study concluded that ostarine can be safely used in the prevention and treatment of muscle loss or bone thinning (osteoporosis).

Ostarine is probably the most popular and well-known SARM on the planet (and also the most abused SARM by athletes). At the same time, Ostarine is without a doubt the most clinically studied and tested SARM, and with the largest number of people tested overall. For example, in 2017 alone, he had 24 human clinical trials involving more than 1,500 people. While potential therapeutic benefits for several serious diseases have been scientifically investigated (not just diseases related to muscle loss and bone thinning). The most common possible side effects of low grade were headache, nausea, fatigue and back pain. Other effects observed were transient increases in alanine aminaminase (ALT) levels, decreases in high density lipoproteins (HDL), blood glucose, insulin and insulin resistance. At the same time, all these changed and increased parameters returned quickly to normal after stopping taking Ostarine.

SARM ANDARINE (S-4)

SARM ANDARINE (S-4) Andarine (often used synonyms GTx-007 or S-4) is a non-steroidal selective androgen receptor modulator developed by GTX, Inc. for the treatment of diseases associated with muscle loss, osteoporosis and benign prostatic hyperplasia. In animal studies, SARM Andarine has been shown to have a comparable anabolic effect on skeletal muscle to testosterone propionate, but has many times less androgenic effects (which causes many undesirable and adverse side effects with testosterone). SARM Andarine has been shown to increase strength and muscle mass similar to DHT (5-α-dihydrotestosterone), and is even more effective in preventing bone loss than DHT. In addition, it had an effect on significantly better fat burning.

Andarine has a weaker anabolic effect than both SARMs LGD-4033 and Ostarine, but it also has a lower effect on the possible suppression of endogenous testosterone production. However, Anadrine has not been fully studied in humans, so not all possible effects have been sufficiently investigated. The experience of experimental users and bodybuilders says that SARM Andarine can significantly improve the growth of muscle mass and strength, in addition to the current significant support for burning body fat. However, at doses higher than 50 mg Andarine per day, short-term visual disturbances (excessive yellowing in vision and blurred vision in the dark or dark) are also a frequently mentioned side effect of Andarine. This is due to the fact that the andarine molecule also binds to receptors in the retina, which negatively affects (worsens) vision. However, these unpleasant visual side effects are reported to be temporary during the use and action of Andarine, with them disappearing rapidly after discontinuation.

SARM RAD140 (TESTOLONE)

SARM RAD140 (TESTOLONE) RAD140 (Testolone) is one of the latest non-steroidal selective androgen receptor modulators (SARMs) developed by Radius Health, Inc. in an effort to create a replacement for exogenous testosterone replacement therapy. RAD140 has an excellent affinity for the androgen receptor (Ki = 7 nM, which is a much higher binding affinity for the androgen receptor than testosterone or DHT), and a high selectivity and a strong anabolic effect (approximately 20% stronger compared to testosterone), but many times less possible androgenic effects. This SARM achieves a ratio of anabolic and androgenic effects with an extremely high and favorable value of up to 90: 1, which cannot be achieved by any hitherto known other SARM. RAD-140 also has an extremely weak interaction with progesterone and estrogen due to the fact that it does not react with other steroid hormone receptors to any significant extent.

RAD140 effectively stimulates the growth of muscle mass, comparable to some anabolic steroids, but is significantly safer compared to steroids. Due to its excellent anabolic properties, is this SARM also very popular with bodybuilders, and those who experiment with its use at their own risk have reported a large increase in strength and muscle mass during its use. In addition to highly effective in stimulating muscle growth and maintaining and increasing bone density, SARM RAD140 has been shown to have significant neuroprotective effects, and may be useful in preventing Alzheimer’s disease and other neurodegenerative disorders in which testosterone deficiency plays a significant role.

At higher doses of RAD140, some possible side effects are also more likely. The most commonly reported side effects include suppressed levels of natural testosterone, possible anxiety, depression or nausea, and excessive hair loss in men (which stops after stopping RAD140 treatment). Some people predict its possible liver toxicity (but this has not yet been credibly and sufficiently scientifically proven). The long-term effects of SARM RAD140 have not been sufficiently investigated and known.

SARM YK11

SARM YK11 YK-11 is a synthetic steroidal selective androgen receptor modulator (steroidal SARM) based on 5-α-dihydrotestosterone (DHT). It is so far the only SARM that is able (in addition to effects on androgen receptors) to increase the expression of follistatin (FST), which plays a key role in the strong anabolic effects of YK11. YK11 is a hybrid SARM – it can be considered and meets the conditions to be not only a SARM but also a steroid and a myostatin inhibitor. Also YK11 differs from other “common" non-steroidal SARMs" (such as LGD-4033, Ostarine or RAD140) not only in that it is a steroidal SARM, but also in that it is only a partial AR agonist (not a full AR agonist). While full agonists activate AR with the maximal response that an agonist can elicit at a receptor, partial agonists have only partial activity at the receptor (compared to full agonists). However, the main strength and high anabolic effect of SARM YK11 on muscle growth is mainly due to the fact that it induces follistatin (FST) expression.

However, YK11 is one of the least SARMs studied to date, and has not yet been tested on humans. Therefore, no relevant information on its effects as well as possible side effects based on a scientific basis is available. The only source of information as YK11 has shown its effects is the shared experience of experimental users and bodybuilders on the Internet (who tried to use it at their own risk). They confirmed a significant anabolic effect of YK11 on muscle growth. Regarding the side effects reported, some of the side effects typical of steroids, such as testosterone suppression, fatigue, aggression, joint pain, excessive hair loss or mild acne, are most commonly mentioned.

Due to the 4 methylated groups present in the structure of YK11 its partial harmfulness to the liver can also be expected. These experimental users describe the hepatotoxicity of YK11 as relatively mild (as shown by the results of their laboratory blood tests, with minimal differences in their liver enzymes). The possible harmfulness to the liver (albeit only partially or perhaps low) and the fact that YK11 has not yet been scientifically and clinically tested on humans are certainly adequate reasons for caution and for us to consider it less safe than others mentioned non-steroidal SARMs which have already been sufficiently clinically tested and have shown a good safety profile and tolerability in the test subjects.

References and Resources

  1. Selective androgen receptor modulator from Wikipedia, the free encyclopedia, https://en.wikipedia.org/wiki/Selective_androgen_receptor_modulator
  2. Ke HZ, Wang XN, O’Malley J, Lefker B, Thompson DD. Selective androgen receptor modulators–prospects for emerging therapy in osteoporosis. PMID 16340136
  3. Yuichiro Kanno, Ritsuko Hikosaka, Shu-Yun Zhang, Yoshimi Inoue, Takayuki Nakahama, Keisuke Kato, Akemi Yamaguchi, Nobuaki Tominaga, Shinya Kohra, Koji Arizono, Yoshio Inouye. (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor. 2011;34(3):318-23. doi 10.1248/bpb.34.318. PMID: 21372378
  4. Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT. Pharmacodynamics of selective androgen receptor modulators". The Journal of Pharmacology and Experimental Therapeutics. 1334–40. doi:10.1124/jpet.102.040840. PMC 2040238. PMID 12604714
  5. Xuqing Zhang, Zhihua Sui. Deciphering the selective androgen receptor modulators paradigm. 2013 Feb;8(2):191-218. doi: 10.1517/17460441.2013.741582. Epub 2012 Dec 12. PMID: 23231475
  6. Ostarine ENOBOSARM 841205-47-8 GTx-024, https://pubchem.ncbi.nlm.nih.gov/compound/Enobosarm. C19H14F3N3O3
  7. Shehzad Basaria, Lauren Collins, E. Lichar Dillon, Katie Orwoll, Thomas W. Storer, Renee Miciek, Jagadish Ulloor Anqi Zhang, Richard Eder, Heather Zientek, Gilad Gordon, Syed Kazmi, Melinda Sheffield-Moore, and Shalender Bhasin. The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men. 2013 Jan; 68(1): 87–95. Published online 2010 Mar 28. doi: 10.1093/gerona/gls078 PMCID: PMC4111291 PMID: 22459616
  8. Yuichiro Kanno, Rumi Ota, Kousuke Someya, Taichi Kusakabe, Keisuke Kato, Yoshio Inouye. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. 2013;36(9):1460-5. doi: 10.1248/bpb.b13-00231. PMID: 23995658
  9. Zachary J. Solomon,a Jorge Rivera Mirabal, M.D.,b Daniel J. Mazur, M.D.,b Taylor P. Kohn,a Larry I. Lipshultz, M.D.,b,c and Alexander W. Pastuszak, M.D. Ph.D.b,c. Selective Androgen Receptor Modulators (SARMs) – Current Knowledge and Clinical Applications. Published online 2018 Nov 30. doi: 10.1016/j.sxmr.2018.09.006. PMCID: PMC6326857. NIHMSID: NIHMS1509921. PMID: 30503797
  10. Ramesh Narayanan, Christopher C. Coss, and James T. Dalton. Development of Selective Androgen Receptor Modulators (SARMs). Published online 2017 Jun 15. doi: 10.1016/j.mce.2017.06.013. PMCID: PMC5896569 NIHMSID: NIHMS955182 PMID: 28624515
  11. Jiyun Chen, Juhyun Kim, and James T. Dalton. Discovery AND Therapeutic Promise OF Selective Androgen Receptor Modulators. 2005 Jun; 5(3): 173–188. doi: 10.1124/mi.5.3.7 PMCID: PMC2072877 NIHMSID: NIHMS32217 PMID: 15994457
  12. Barbara, Mary; Dhingra, Sadhna; Mindikoglu, Ayse L. MD, Drug-Induced Liver Injury Associated With Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033). ACG Case Reports Journal: June 2020 – Volume 7 – Issue 6 – p e00409. doi: 10.14309/crj.0000000000000409
  13. Andrés Negro-Vilar. Selective Androgen Receptor Modulators (SARMs): A Novel Approach to Androgen Therapy for the New Millennium. The Journal of Clinical Endocrinology & Metabolism, Volume 84, Issue 10, 1 October 1999, Pages 3459–3462, https://doi.org/10.1210/jcem.84.10.6122
  14. Terry R. Brown. Nonsteroidal Selective Androgen Receptors Modulators (SARMs): Designer Androgens with Flexible Structures Provide Clinical Promise. Endocrinology, Volume 145, Issue 12, 1 December 2004, Pages 5417–5419, https://doi.org/10.1210/en.2004-1207
  15. Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD (June 2009). Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. Journal of Medicinal Chemistry. 52 (12): 3597–617. enw454 doi:10.1021/jm900280m. PMID 19432422
  16. Gao W, Kim J, Dalton JT. “Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands". Pharmaceutical Research. 23 (8): 1641–58. doi:10.1007/s11095-006-9024-3. PMC 2072875. PMID 16841196

Disclaimer:  Please keep in mind that all of our products are sold solely for scientific research purposes